fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Fed Fear Mongering Takes Down The Markets Again This Week – $BBBY $CYN $INM $TSLA Rise!

By John F. Heerdink, Jr.
Quote of the Day: – “We know what we are, but know not what we may be.” – William Shakespeare


The markets overall experienced yet another broadly-based sell-off this week pressured by last week’s Fed’s Minutes & individual FOMC voters sounding off hawkishly, and then this week’s Fed Chair Jerome Powell confirmation that the central bank is committed to raising rates “expeditiously” to bring down inflation & is now pointing toward an interest rate hike of 50 basis points in May as inflation is running at a pace that is the fastest that he has seen in more than 40 years. He believes this must be done to restore “stability” and is unwilling to state that it has reached a ‘peak’. This type of loose communication between meetings, this time at an IMF panel hosted by CNBC, is growing fear amongst investors. Fear begets fear and  ‘selling begets selling’ and the markets are most certainly following suit at the moment.

In concert with this negative rhetoric, the yield curve rose again as the 2-yr treasuries moved up 20 basis points to close at 2.72%, while the 10-yr treasuries rose to close at 2.91% up 20 basis points. The 30-year fixed rates are now over 5% as market participants price in higher fed interest rates.

Oil Prices also remained well above a sustainable level closing at $101.61/bbl, but at least moved down 5.1% for the week. Oil dropped after the International Monetary Fund (IMF) stated that the global economic recovery will “slow significantly” in 2022 primarily caused by the Russian-Ukraine war and the resulting disruption of commodities. In addition, the IMF believes that global GDP will rise 3.6% in 2022, well below their 4.4% projection that was produced not long ago in January 2022. They also added that in 2023 growth will come in at 3.6% notching down from their 3.8% projection. 

The markets also swallowed a mixed bag of reports from number of noted companies including a disappointing report from Netflix (NLFX) where they reported that they lost 200k paid subscribers in Q1 & believes it will lose another 2M subscribers in Q2, which set a negative tone in the markets. 

As a result, the major indices closed lower and it was exhausting week for most. The S&P 500 closed at 4,271.78 (-2.8%) for the week and is now down 10.4% YTD. 9 of the 11 sectors ended in the red & were led by the communication services sector’s 7.7% fall & energy’s 4.6% decline. The 2 positive sectors were the real estate moving up 1.2% & the consumer staples ticking up .4%. The Dow 30 moved lower closing at 33,811.40 (-1.9%) and is now down 7% YTD, & the growth oriented Nasdaq experienced yet another decidedly negative week as it closed at 12,839.29 (-3.8%) and is now down 17.9% YTD.  The small caps also got hit again this week as the Russell 2000 closed at 1,940.66 (-3.2%) and is now down 13.6% YTD. The MicroCaps ended down as well over the last 5-days as the iShares Micro-Cap ETF (IWC) closed at $120.42, -4.53% and is down 13.82% YTD.

The biotech stocks ended the week significantly lower on the larger side with the Nasdaq Biotechnology ETF (IBB) closing at $123.04, -5.98% over the last 5-days, -19.38% YTD. The NYSE ARCA Biotech Index (^BTK) also closed sharply lower at 4,891.71, -6.43% over the last 5-days. On the smaller side of the biotech markets, represented to a degree by the SPDR S&P Biotech ETF (XBI), closed at $79.84 & down 9.03% over the last 5-days and is now down 28.69% YTD after stabbing a new 52-week low of $79.67 on Friday. When will the winter freeze thaw for this sector? The 52-week range is is now $79.67-$141.50). 

The macroeconomic schedule served up a number of reports again this week. On Monday, the NAHB Housing Market Index report for April came in down 2 points to 77. On Tuesday, the Housing starts report confirmed a rise of .3% M/M in March to a seasonally adjusted annual rate of 1.793M. Housing permits came in higher up .4% M/M to a seasonally adjusted annual rate of 1.873M. On Wednesday, the existing home sales report confirmed a 2.7% M/M drop in March to a seasonally adjusted annual rate of 5.77M, while total sales in March dropped a sizable 4.5% Y/Y. In concert, the weekly MBA Mortgage Applications Index report showed a 5% drop. On Thursday, the Initial jobless claims report for the week ending April 16 confirmed a drop by 2k to 184k, while the continuing jobless claims report for the week ending April 9 clocked in lower by 58k to 1.417M. The Philadelphia Fed Index report for April showed a nearly 10 point drop to 17.6. The Conference Board’s Leading Economic Index (LEI) report showed a rise by .3% M/M in March. On Friday, the preliminary IHS Markit Manufacturing and Services PMIs for April where the manufacturing reading showed a nearly 1 point rise to 59.7 M/M & the services reading showed a unary 4 point to 54.7 M/M.


EV, TECH, CONSUMER, FINANCIALS

Apple (AAPL) closed at $161.79, -2.12% over the last 5-days. On April 14, Apple announced that its suppliers more than doubled their use of clean power over the last year, with over 10 gigawatts operational today out of nearly 16 gigawatts in total commitments in the coming years. In 2021, these renewable projects avoided 13.9 million metric tons of carbon emissions. The projects online today will support greenhouse gas reductions equivalent to removing 3 million cars from the road for one year.

On April 6, Apple® previewed Apple Myeongdong, a new retail store located in the center of Seoul’s vibrant and bustling shopping district. Serving as Apple’s largest store in South Korea, this new space will invite customers to discover Apple’s latest products, receive best-in-class support from highly knowledgeable Apple Specialists, and participate in educational Today at Apple® sessions. “We are thrilled to deepen our relationship with our Korean customers with the opening of this special store in Myeongdong,” said Deirdre O’Brien, Apple’s senior vice president of Retail + People. “Our incredible retail team is ready to welcome the local community, and we invite everyone to find endless inspiration as they explore Apple’s innovative products and services.”
 
On April 5, Apple announced it will host its annual Worldwide Developers Conference (WWDC) in an online format from June 6 through 10, free for all developers to attend. Building on the success of the past two years of virtual events, WWDC22 will showcase the latest innovations in iOS, iPadOS®, macOS®, watchOS®, and tvOS®, while giving developers access to Apple engineers and technologies to learn how to create groundbreaking apps and interactive experiences.
 
On March 31, Apple® announced that Apple Business Essentials™ is now available to all small businesses in the US. The new service brings together device management, 24/7 Apple support, and iCloud® storage into flexible subscription plans. Apple also unveiled new AppleCare+℠ for Business Essentials options that can be added to any plan. Additionally, a two-month free trial will be available to all customers, including those who have been using Apple Business Essentials in beta.
 
On March 30, Apple® announced a $50 million Supplier Employee Development Fund that will expand access to learning opportunities and skills development. The fund also includes new and expanded partnerships with leading rights advocates, universities, and nonprofits to drive Apple’s ongoing work to empower supplier employees and drive improvements in knowledge of and respect for workplace rights across industries. As part of the new $50 million commitment, and building on Apple’s long history in the space, the company is working alongside supply chain partners to amplify worker voice. That includes supporting the worker rights programs created by the International Labour Organization (ILO) for people in the electronics sector, and the work the International Organization for Migration (IOM) is doing to expand rights trainings and scale its industry-leading responsible labor recruitment tools. “We put people first in everything that we do, and we’re proud to announce a new commitment to accelerate our progress and provide even more opportunities for people across our supply chain,” said Sarah Chandler, Apple’s senior director of Environment and Supply Chain Innovation. “Together with rights advocates and education leaders, we are continuing to drive new innovation to support people and the planet.”
 

tesla

EV giant Tesla (TSLA) closed at $1005.05, +2.05% over the last 5-days and is splitting its stock once again.

On April 20, Tesla reported that Q1 sales had jumped 81% even in the face of supply-chain disruptions, while Elon Musk promised a robotaxi for 2024.

Shares of Cyngn (CYN), a developer of innovative autonomous driving software solutions for industrial and commercial enterprises, skyrocketed to close at $2.69, +133.91% over the last 5-days. On April 21, Cyngn announced the official launch of DriveMod Kit, a turnkey autonomous vehicle (“AV”) solution for which Cyngn filed a patent in February 2022. DriveMod Kit’s inaugural manufacturing run started coming off the assembly line in the first half of April 2022. Containing all the advanced sensors and hardware components needed for AV technology integration, DriveMod Kit is designed to streamline retrofitting of existing industrial vehicles or simplify integration onto newly manufactured vehicles. We believe that by eliminating traditional barriers to autonomous vehicle adoption, such as high costs and complex installations, DriveMod Kit will facilitate rapid adoption of autonomous vehicles across a wide range of industrial and commercial domains. “We are excited to have launched production of DriveMod Kit for Columbia’s Stockchaser. With 883,000 new material-handling vehicles sold each year in the U.S., DriveMod Kit creates a sizable opportunity for Cyngn to lead the rapid adoption of turnkey AV solutions for both retrofit and new vehicles. Installation can be done quickly and does not require special training. Anyone who works on these vehicles can retrofit an existing Columbia Stockchaser into a fully autonomous vehicle with very little effort. DriveMod Kit is a complete AV integration solution, a game-changer that eliminates traditional barriers to autonomous vehicle adoption,” said Lior Tal, Cyngn’s CEO.


Shares of JPMorgan (JPM) closed at $126.81, +.55% over the last 5-days. On April 7, Chase announced that it will pilot public fast electric vehicle charging stations across 50 of its U.S. branches beginning this summer. This adds to the firm’s efforts to promote environmental sustainability in its retail locations as it also aims to expand on-site solar power to approximately 400 additional branches by the end of 2022. To bring the charging stations to branches, the bank partnered with EVgo, a pioneer and innovator in transportation electrification. The company builds, owns and operates the nation’s largest network of public DC fast chargers, powered by 100% renewable energy.

JPMorgan will host a conference call to review first-quarter 2022 financial results on Wednesday, April 13, 2022 at 8:30 a.m. (EDT). The results are scheduled to be released at approximately 7:00 a.m. (EDT). The live audio webcast and presentation slides will be available on www.jpmorganchase.com under Investor Relations, Events & Presentations.

On March 24, Chase, the largest co-brand card issuer in the U.S., and IHG® Hotels & Resorts announced the launch of the new IHG® Rewards Premier Business Mastercard®, with Mastercard as the exclusive payments network, designed to help small business owners turn everyday expenses into meaningful travel rewards. In tandem with this news, Chase and IHG also activated new and enhanced benefits across the IHG® Rewards Traveler and Premier Consumer Mastercard® products.

On March 1, JPMorgan Chase announced five organizations will receive philanthropic capital as part of the firm’s $400 million five-year commitment to improve housing affordability and stability for underserved households, particularly in Black, Hispanic and Latino communities.

Amazon.com, Inc. (NASDAQ: AMZN) $2,887, -4.85% over the last 5-days.

On April 20, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company announced it has committed more than $30 million to early stage startups led by Black, Latino, LGBTQIA+, and women founders as part of its new AWS Impact Accelerator. Over the three-year commitment, AWS will provide funding and guidance for a series of programs that will help these organizations build successful companies. Each qualifying startup receives up to $225,000 in cash and credits, extensive training, mentoring and technical guidance, as well as introductions to Amazon leaders and teams, networking opportunities with potential investors, and ongoing advisory support. Eligible startups can now apply to the first of these programs, the AWS Impact Accelerator for Black Founders.

Shares of Microsoft Corp. (MSFT) closed at $274.03, -2.07% over the last 5-days.

On April 21, The Kraft Heinz Company and Microsoft Corp. announced they are joining forces to develop solutions designed to accelerate the consumer goods giant’s transformation and enable a more resilient supply chain. The initiative is one of Kraft Heinz’s largest technology investments to date and a key driver of the company’s ambitious AGILE@SCALE approach. With Microsoft Azure as its preferred cloud platform, Kraft Heinz will migrate the majority of its global datacenter assets to Azure and its enterprise resource planning (ERP) software to SAP on Azure. Through this transformation, Kraft Heinz expects to reimagine its day-to-day operations, create a more collaborative supply chain, and enhance consumer experiences by using real-time predictive analytics to improve inventory transparency and anticipate consumer and channel demand. At the same time, the efficiencies created through the adoption of digital tools from Microsoft are expected to allow the food and beverage leader to continually reinvest into its business.

NVIDIA (NVDA) closed $195.15, -8.2% over the past 5-days. On March 22, NVIDIA announced the launch of new NVIDIA Omniverse™ features that make it easier for developers to share assets, sort asset libraries, collaborate and deploy AI to animate characters’ facial expressions in a new game development pipeline. With the NVIDIA Omniverse real-time design collaboration and simulation platform, game developers can use AI- and NVIDIA RTX™-enabled tools, or easily build custom ones, to streamline, accelerate and enhance their development workflows. New features for game developers include updates to Omniverse Audio2Face™, Omniverse Nucleus Cloud and Omniverse DeepSearch, as well as the introduction of Unreal Engine 5 Omniverse Connector.

Cathie Wood’s ARK Innovation ETF (ARKK) closed at $52.46, -11.07% over the last 5-days.

The Technology Select Sector SPDR Fund (XLK) closed at $143.08, -2.43% over the last 5-days.

Disney (DIS) closed at $1118.27, -9.35% over the last 5-days. Reportedly, the Florida Senate passed a bill to eliminate Disney special status and now Florida governor Ron DeSantis signs bill stripping Disney of special tax status after Disney spoke out against Florida law that limits school instruction about gender identity and sexual orientation or the “D’ont Say Gay” bill.  

Disney will discuss fiscal second quarter 2022 financial results via a live audio webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, May 11, 2022. Results will be released after the close of regular trading on May 11, 2022. To listen to the webcast, please visit www.disney.com/investors.


Shares of McDonald’s (MCD) closed at $250.17, -.14% over the last 5-days .

GOLD & SILVER

Gold prices closed at $1,933, -$18/oz. & silver prices closed at $24.22, -$.71/oz. for the week. Hecla Mining (HL) closed at $6.06, -15.24% over the last 5-days & First Majestic (AG) closed at $11.70, -17.84% over the last 5-days as BMO Capital cut its price target to $12.


MEMES REPORT

AMC Entertainment (AMC) closed at $16.52, -8.32% over the last 5-days. On April 12, AMC announced it finalized a deal with Bow Tie Cinemas to purchase and operate seven locations in Connecticut, upstate New York and Annapolis, Maryland.

GameStop (GME) closed at $138.22, -8.32% over the last 5-days. GME plans to split its stock. GME announced that its fourth quarter and full year fiscal 2021 results after the market closed on Thursday, March 17, 2022. Here are a few highlights: Generated net sales of $2.254 billion for the quarter, compared to $2.122 billion in the fourth quarter of 2020 and $2.194 billion in the fourth quarter of 2019, Established new and expanded brand relationships, including with PC gaming companies such as Alienware, Corsair and Lenovo, that contributed to sales growth in the quarter, Grew PowerUp Rewards Pro members by 32% on a year-over-year basis, taking total membership to approximately 5.8 million, & Entered into a partnership with Immutable X that is intended to support the development of GameStop’s NFT marketplace and provide the Company with up to $150 million in IMX tokens upon achievement of certain milestones.

Bed Bath & Beyond Inc. (NASDAQ: BBBY) shares closed at $17.46, +.75% over the past 5-days. On April 13, BBBY reported financial results for the fourth quarter of Fiscal 2021 ended February 26, 2022 highlighting Q4 Net Sales of $2,051M; Comparable Sales of (12)% Impacted by Ongoing Supply Chain and Inventory Availability Challenges; Q4 GAAP Gross Margin of 28.3%; Adjusted Gross Margin of 28.8% including 360bps of Higher than Expected, Escalating Supply Chain Costs. Excluding Supply Chain Cost Increases, Q4 Adjusted Gross Margin of 32.4%, & Second Year of Transformation to Continue in Fiscal 2022.

Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) closed at $1.11, -5.93% over the last 5-days.  On April 1, Seanergy  announced that its Annual Report on Form 20-F for the fiscal year ended December 31, 2021 (the “Annual Report on Form 20-F”) has been filed with U.S. Securities and Exchange Commission. The Annual Report on Form 20-F may also be accessed through the Company’s website, www.seanergymaritime.com, at the “Investor Relations” section under “Financial Reports”.

On March 16, Seanergy announced that it has successfully completed marine biofuel trials in cooperation with one of its major charterers, NYK Line, on one of the Company’s Capesize Vessels. The biofuel is a 0.50% VLSFO blended with a waste-based and ISCC certified FAME component at a 90% – 10% ratio. Advanced real time monitoring instruments and AI have been used to assess the results of the trials.

CRYPTO & BITCOIN

Bitcoin (BTC) closed at $39,620.16, -2.95% over the last 5-days.  

ENERGY

The Energy Select Sector SPDR Fund or ETF (XLE) closed at $76.20, -4.57% over the last 5-days. Chevron (CVX) closed at $160.95, -6.20% over the last 5-days. 


NEXT WEEK

Back to 5 volatile trading sessions next week and probably more Fed negative inflation fighting rhetoric. Woo Hoo!

VP WATCHLIST UPDATES

Please review our complete VP Watchlist that includes Apple (AAPL), Disney (DIS), Tesla (TSLA) & a select group of emerging names.  The pages will allow you to learn more and keep up with these companies daily.

For now, see the summaries or five of the emerging companies from the VP Watchlist below:


Shares of INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, closed at $6.85, -17.57% over the last 5-days. The 52-wk range is $6.18 – $30.37.

    • On April 13, INmune bio announced dosing of the first patient enrolled in its Phase 2 trial using XPro1595 (XPro™) to treat neuroinflammation as a cause of Alzheimer’s disease (AD). The Phase 2 multicenter, international trial is a blinded, randomized, placebo-controlled six-month Phase 2 trial designed to evaluate XPro™ to treat cognition and function in patients with mild AD and biomarkers of inflammation. The company plans to enroll patients at sites located near major metropolitan areas in Australia, in Canada and in the United States. “The Phase 1 study data clearly showed an improvement in multiple biomarkers related to AD pathology, including a reduction in neuroinflammation and neurodegeneration, and an improvement in biomarkers of neurorepair and neuron communication,” said Dr. C.J. Barnum, INmune Bio’s Vice President of CNS Development. “This Phase 2 study will determine whether improvement in these biomarkers translates into a clinical benefit of improved cognition and function in patients with mild AD and biomarkers of inflammation.”
    • On April 11, INmune Bio announced data demonstrate that INmune Bio’s INB03 reverses MUC4 experssion in HER2+ BC cell line (JIMIT-1) to re-establish sensitivity to trastuzumab (traz) and tyrosine kinase inhibitors (TKI). Mucin 4 (MUC4), a glycoprotein is an easily measured biomarker in women with breast cancer. Previously, INmune Bio reported MUC4 expression predicts worse survival in women with HER2+ BC (p≤0.04). Study results show this new evaluation focused on the effects of MUC4 expression on the immune cells of the tumor microenvironment (TME) in HER2+ BC. These data were presented here today at the American Association of Cancer Research Annual Meeting in 2022, held in New Orleans April 8-13. The findings of this study predict that women with MUC4+/HER2+ BC are expected to have fewer tumor infiltrating lymphocytes (TILs) than women who do not express MUC4 (p=0.018). In a nude mouse model of MUC4+HER2+ BC, the combination of INB03+traz increased the number of activated NK cells (p=0.01) and anti-tumor macrophages (p=0.01) in the TME. In this nude mouse model, anti-tumor macrophage function is more important than NK cell function in controlling tumor growth. Dr. Roxana Schillaci of Instituto de Biología y Medicina Experimental in Buenos Aires stated, “We have previously shown that MUC4 expression correlates with resistance to traz and TKI. We can add third resistance mechanism to the list – an immunologically “cold” TME. These three resistance mechanisms are driven by soluble TNF produced by the tumor and are reversed by INB03 in the animal models.” RJ Tesi MD, CEO of INmune Bio stated, “Resistance to immunotherapy occurs in about a third of women with HER2+ BC. MUC4 is a biomarker of resistance that can be determined from the patient’s biopsy. Identifying a modifiable resistance factor early may allow the clinical team to optimized immunotherapy to improve outcome.”
    • On April 4, INmune Bio highlighted key findings from the NK Cells in Solid Tumors workshop. Dr. Mark Lowdell, INmune Bio’s Chief Scientific Officer (CSO), led the workshop on the role of NK cells in treatment of solid tumors during the Innate Killer Summit in San Diego (March 30 -April 1, 2022). The conference is widely viewed as one of the most important in translational NK cell immunotherapy. Two consistent themes of this year’s conference were the importance of memory-like NK cells and the poor in-vivo survival of adoptively transferred allogeneic NK cells, with or without genetic modification. Strategies to improve NK cell “fitness” and improve NK cell metabolism were at the forefront. NK cell dysfunction and poor survival in the recipient and, in particular the TME may be due to damaged mitochondria – considered the “powerplants” of the cell that are essential for survival. Dr. Lowdell observed that INKmune™, unlike IL15 and other NK-activating cytokines, simultaneously upregulates all mitochondrial survival proteins and more than 40 nutrient receptors on the NK cell. These unique changes may help INKmune-primed NK cells survive and thrive in the hypoxic immunosuppressive TME. Data from patients treated with INKmune™ have shown tumor killing memory-like NK cells present in peripheral blood and bone marrow for at least 15 weeks after INKmune™ therapy and provoked a lot of discussion about whether INKmune™ can be used in combination with adoptive NK therapies to sustain the memory-like phenotype and increase survival. Dr. Lowdell, CSO of INmune Bio stated, “For NK cells to become relevant in the treatment of solid tumors, several problems must be solved. At the workshop, we presented how INKmune™, INmune Bio’s NK cell therapeutic, may solve these problems as demonstrated by published and unpublished pre-clinical and clinical data from the INKmune™ Phase I trial in high-risk MDS. A common therapeutic strategy is giving ex vivo-activated NK cells from peripheral blood which are conditioned to normal oxygen levels. Hoping that these cells track to the tumor and aren’t inhibited by the hypoxic, immunosuppressive TME does not align with our understanding of tumor biology in patients. Activation of tumor-resident NK cells in vivo is likely to be important for patient treatment and tumor-activated NK cells seem to be better than cytokine-primed NK cells in surviving the hostile hypoxic and immunosuppressive environment of the TME. As far as we know, INKmune™ is the only agent which can give the pleiotropic NK activating signals that improve NK function in the hostile immunosuppressive and hypoxic environment of the TME. I came away from this meeting even more convinced that INKmune™ can have a major impact in current and future NK immunotherapies in hematological and solid tumors and with a list of potential new collaborators for our future trials.”  
    • On March 25, INMB announced reviews findings from data presented at AD/PD™ 2022 – International Conference on Alzheimer’s and Parkinson’s diseases. The AD/PD™ 2022 International Conference was from March 15-20 in Barcelona, Spain. “The field of AD is changing rapidly as treatments beyond amyloid and tau are explored. Targeting neuroinflammation, the use of biomarkers, and novel clinical trial designs are changing the way drugs are developed for this challenging disease,” said R.J. Tesi, INMB’s CEO. “In my opinion, there are three key observations that put the nine presentations by INmune Bio in perspective. We remain convinced that targeting glial activation with Xpro™ is a smart strategy.”
    • On March 23, eight Form 4’s were filed representing a significant increase in insider buying in INMB’s stock. Please see filings at the direct link at sec.gov
    • On March 15,  INmune Bio announced nine pieces of data, including oral symposia, would be presented at AD/PD™ 2022 – International Conference on Alzheimer’s and Parkinson’s diseases. The AD/PD™ 2022 International Conference is being held from March 15-20 in Barcelona, Spain. Raymond J. Tesi, Ph.D, Chief Executive Officer of INmune Bio, commented, “This is the first time many clinician teams in Europe and UK have been exposed to XPro™ and INmune Bio’s approach to treatment of Alzheimer’s Disease,” said RJ Tesi. “These nine presentations show the versatility of XProTM and the importance of neuroinflammation in the pathogenesis of neurodegenerative disease. The presentations provide a great overview of XPro™ for the treatment of AD, introducing the novel biomarkers INmune is using, and how the results of the Phase I trial provided insight into the design the Phase II trials in mild cognitive impairment and Mild Alzheimer’s.” LEARN MORE HERE. 
    • On March 3, INmune Bio reported its financial results for the year ended December 31, 2021 and provided a business update. INmune Bio highlighted that in December, the Company reported data from the first patient treated with INKmuneTM in the myelodysplastic syndrome (MDS) Phase I clinical trial. More than 100 days after the course of INKmuneTM therapy, 60% of the patient’s NK cells showed the activated, tumor killing memory like NK cells phenotype, a fourfold increase from pre-treatment. The patient’s memory like NK cells killed >70% of NK resistant tumor cells in an in vitro assay. The patient remains well and with an ECOG status of 0, a two-point drop from pre-treatment. Additionally, two patients were treated with INKmuneTM under compassionate use after having failed at least one allogeneic bone marrow transplant. One of the two patients has been discharged home, one remains hospitalized. In all cases, INKmuneTM therapy was well tolerated, safe and was given without any type of pre-medication or cytokine therapy.


RJ Tesi, M.D., Chief Executive Officer of INmune Bio stated, “These patients demonstrate the unique attributes of INKmuneTM therapy in patients with high-risk MDS/AML. INKmuneTM converted the patient’s resting NK cells into cancer killing memory like NK cells. The memory like NK cells killed NK-resistant cancer cells in an in vitro assay. Both these attributes lasted four months, a trait we are calling therapeutic persistence. We are continuing to screen patients for enrollment into the trial and are in process of expanding the number of clinical trial sites.”


    • On Jan. 25, INmune announced that the company has entered into a pre-clinical research collaboration with Chinese University of Hong Kong (CUHK) to evaluate INKmune™ — the company’s pseudokine NK cell priming platform — in nasopharyngeal cancer (NPC), a type of head and neck cancer. The Strategic Partnership Award for Research Collaboration, which was granted by the CUHK Office of Academic Links, is between Prof. Michael Tong at CUHK and Prof. Mark Lowdell at University College London (UCL) and Chief Scientific Officer of INMB. The project provides INMB scientists working at UCL with access to the only three proven NPC cancer cell lines to test the ability of INKmune-primed NK cells to kill NPC tumors.
       
      Prof. Lowdell stated, “Our colleagues at CUHK have been studying NK cell responses to NPC for many years but have not yet translated them into clinical trials. They have shown the need for cytokine activation with IL2 or IL15 to achieve tumor killing. We believe pseudokine activation by INKmune will provide all the relevant NK activating signals of IL2 and IL15 plus a host of other critical NK survival signals and generate memory-like NK cells. We are confident that these INKmune primed cells will kill NPC tumor cells very effectively and we look forward to a mutually beneficial collaboration.”
       
      RJ Tesi, INmune Bio’s Chief Executive Officer stated, “Over 180,000 cases of NPC were diagnosed last year with 85% originating in Asia. Current treatments are quite poor, leading to high mortality rates. History of EBV infection (commonly known as mono) and genetic polymorphisms drive the incidence of the disease. This peer-reviewed grant and international collaboration targeting what has historically been a difficult to treat solid tumor validates the versatility of INKmune. We look forward to translating this work to the clinic in the near future.”
  •  



  • Shares of InMed Pharmaceuticals, Inc. (NASDAQ: INM), a leading clinical-stage pharmaceutical company developing cannabinoid-based drug candidates for high unmet medical needs and IntegraSyn, a proprietary and cost effective manufacturing approach for synthesized rare cannabinoids, closed at $.9001, +3.1% over the last 5-days.  Please visit the INM page at our website to learn more and check out the videos section too. The 52-wk range is $.652 – $3.86
    • April 21, InMed announced it has launched B2B sales of the rare cannabinoid cannabidivarin (“CBDV”) to wholesalers, suppliers and end-product manufacturers in the health and wellness sector through its US subsidiary, BayMedica LLC. “Ensuring a reliable, large volume source of highly pure, bioidentical CBDV is an important step forward in the health and wellness sector. CBDV has been researched for its therapeutic potential in several disease areas such as autism spectrum disorder,” said Shane Johnson, MD, SVP and General Manager of BayMedica. “Whether you are a researcher or product developer at a multinational consumer package goods (‘CPG’) company, the ability to access highly pure and consistent active ingredients, free from contaminants typically found in plant-sourced cannabinoids such as pesticides, heavy metals, or potentially even THC, is a fundamental requirement. BayMedica’s cannabinoid manufacturing technologies provides exactly that value and we are excited to continue to introduce to the market additional rare cannabinoids that have previously not been abundantly accessible, including adding THCV to our portfolio in the immediate future.” LEARN MORE.
    • On  Feb. 15, Inmed announced the appointment of Gerard (Jerry) P. Griffin III as Vice President of Sales and Marketing at BayMedica, a wholly owned subsidiary of InMed. Mr. Griffin will oversee the commercialization of BayMedica’s health and wellness business including the existing products and the launch of new rare cannabinoid products. Mr. Griffin has a wealth of experience across various markets and with numerous cannabinoid products, and a proven track record as a seasoned sales executive. He has held several senior positions at both privately and publicly held companies including Fortune 500 companies. Most recently, Mr. Griffin was the Vice President of Sales and Business Development at Creo Ingredients, a biotechnology-based ingredient company that produces rare cannabinoids. Prior to Creo, he was the President of a successful wellness company, overseeing all aspects of a business that develops and distributes cannabinoid-based products. With his extensive hands-on experience in the rapidly expanding cannabinoid industry, he brings significant real-world knowledge across the entire value chain to the Company.

    • On Feb. 14, InMed announced financial results for the second quarter of fiscal year 2022 which ended December 31, 2021. They highlighted that they completed the acquisition of BayMedica, a rare cannabinoid manufacturing and commercialization company in the health and wellness sector, they strengthened IP with patent filing for use of rare cannabinoids for the treatment of neurodegenerative diseases, they initiated the commercial rollout of an additional rare cannabinoid, CBT- first of several rare cannabinoid launches planned for the first half of 2022, & they advanced the pharmaceutical drug development programs in EB, glaucoma and neurodegenerative diseases. READ THE BALANCE OF THE RELEASE.

    • On Jan. 19, InMed announced that it has launched B2B sales of the rare cannabinoid cannabicitran (CBT) into the health and wellness sector. CBT is the first of several new product launches planned for the first half of 2022. InMed’s subsidiary, BayMedica, has received initial purchase orders and has commenced commercial sales of the ultra-rare cannabinoid CBT. CBT is the second rare cannabinoid to be launched by BayMedica, which also sells CBC wholesale as a raw ingredient to the health and wellness sector. Additionally, commercial scale production of cannabidivarin (CBDV) is underway, with tetrahydrocannabivarin (THCV) production scheduled to follow shortly thereafter. The Company expects to produce over 100kg of CBDV and THCV in the coming months to meet anticipated initial demand. Shane Johnson, SVP and General Manager of BayMedica stated, “We are delivering on our objective to launch additional rare cannabinoids in early 2022 in response to inbound demand. By midyear, we expect to have at least four rare cannabinoids available for the health and wellness markets, positioning us as a leading large scale supplier of high quality rare cannabinoids in these sectors. The launch of CBT further demonstrates our ability to produce rare cannabinoids at commercial scale, an achievement that very few companies have been able to accomplish. We are pleased with initial demand and we expect to grow sales over the coming quarters as we continue to expand our product portfolio of rare cannabinoids.” This emerging market is expected to grow significantly due to the increasing awareness of the potential benefits of cannabinoid-based products. According to the December 2021 Grand View Research report, the retail market for rare cannabinoids is expected to reach US$26 billion by 2028 with a forecasted compounded annual growth rate (CAGR) of >20% during the same period. With the availability of these rare cannabinoids at commercial scale, product manufacturers and consumer brands now have the ability to deliver differentiated products, including augmenting existing CBD-based products, to consumers in the health and wellness marketplace.
    • On Jan. 5th, InMed issued its Annual Letter to Shareholders from President and CEO Eric A. Adams which stated, “Building on a very strong 2021, we are looking forward to 2022 with the continued advancement of our pharmaceutical drug development programs and, with our acquisition of BayMedica, transitioning to becoming a leading B2B supplier of rare cannabinoids to the consumer health and wellness sector. I’m very excited to provide updates on our progress as we begin to commercialize new products and explore an array of rare cannabinoids for their potential therapeutic applications.” Click here to read the letter
    • On Nov. 29, InMed Pharmaceuticals (NASDAQ: INM) received a BUY Recommendation from Raghuram Selvaraju, Ph.D. a sell side analyst at H.C. Wainwright & CO. with a Price Target of $6. His report is titled “Charging After Pharmaceutical-Grade Cannabinoids; Initiating at Buy and $6 PT”.  

  • Shares of Natural-Killer cell (NKcell) focused biopharmaceutical firm Fate Therapeutics (FATE) closed at $34.63, -8.31% over the last 5-days. 
    • Fate announced that the Company will host a conference call and live audio webcast on Wednesday, May 4, 2022 at 5:00 PM ET to report its first quarter 2022 financial results and provide a corporate update. In order to participate in the conference call, please dial (877) 303-6235 (domestic) or (631) 291-4837 (international) and refer to conference ID 9978043. The live webcast can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website beginning approximately two hours after the event.

    • On Jan. 10, Fate announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for FT536, an off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor (CAR) NK cell product candidate. FT536 is derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with four functional elements, including a novel CAR that uniquely targets the α3 domain of the major histocompatibility complex (MHC) class I related proteins A (MICA) and B (MICB). MICA and MICB are stress proteins that are expressed at high levels on many solid tumors. The Company plans to initiate clinical investigation of FT536 as a monotherapy and in combination with tumor-targeting monoclonal antibody therapy for the treatment of multiple solid tumor indications.
    • On Monday, Dec. 13, Fate showcased positive interim Phase 1 data from the Company’s FT596 program for patients with relapsed / refractory B-cell lymphoma (BCL) at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. FT596 is the Company’s off-the-shelf, multi-antigen targeted, iPSC-derived natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with three anti-tumor functional modalities: a proprietary chimeric antigen receptor (CAR) optimized for NK cell biology that targets B-cell antigen CD19; a novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor that has been modified to prevent its down-regulation and to enhance its binding to tumor-targeting antibodies; and an IL-15 receptor fusion (IL-15RF) that augments NK cell activity. “The interim dose-escalation clinical data from our FT596 program in relapsed / refractory B-cell lymphoma demonstrate that off-the-shelf, iPSC-derived CAR NK cells can bring substantial therapeutic benefit to heavily pre-treated patients in urgent need of therapy, with high response rates and meaningful duration of responses,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. “We are particularly pleased with the therapeutic profile that has emerged with FT596 in combination with rituximab, where over half of the patients treated with a single dose of FT596 at higher dose levels achieved a complete response with a favorable safety profile that is clearly differentiated from CAR T-cell therapy. We look forward to assessing a two-dose treatment schedule for FT596 to further define its potential best-in-class therapeutic profile and ability to reach more patients, including those earlier in care.”


  • Shares of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, closed at closed at $1.02, -8.11% over the last 5-days. 
    • On April 20, Atossa announced it has completed enrolling participants in Part B of its Phase 1/2a clinical study of AT-H201 in Australia, consisting of multiple ascending dose cohorts in healthy participants. AT-H201 is being developed as an inhalation therapy for moderately to severely ill hospitalized COVID-19 patients and for “long-haul” patients with post-infection pulmonary disease.“Part B of the study was successfully completed and, subject to approval from the ethics committee, we will now proceed to enroll the next group of participants,” said Steven Quay, M.D., Ph.D., Atossa’s CEO and President. “Despite widespread availability of vaccines, many areas of the world are seeing a recent surge in COVID-19 cases. There continues to be a strong need for additional therapies to combat COVID-19.” LEARN MORE. 
    • On March 8, Atossa announced that the U.S. Patent and Trademark office has issued a new patent further strengthening Atossa’s intellectual property in its proprietary therapy Endoxifen, which is under development for breast cancer and other breast conditions. U.S. Patent No. 11,261,151 (the ‘151 Patent) is titled “Methods for Making and Using Endoxifen” and is directed to compositions of storage-stable Endoxifen and methods of treating hormone-dependent breast disorders using the storage-stable Endoxifen. “We are very pleased with the scope and breadth of this new key patent,” said Dr. Steven Quay, Atossa’s President and Chief Executive Officer. “Patents covering the composition of matter of new therapies are critical to protect markets from generic competition. The ‘151 Patent,’ with its estimated expiration in 2038, strengthens our intellectual property estate and should create long-term stockholder value.”Atossa is developing its proprietary Endoxifen in two clinical settings: one to reduce tumor cell activity in breast cancer patients in the neoadjuvant setting, meaning prior to surgery; and another to reduce dense breast tissue in women. A Phase 2 study is currently underway in women with measurable breast density and Atossa plans to submit a request (IND) to the FDA to open other Phase 2 in the neoadjuvant setting in the next quarter. Atossa’s neoadjuvant program is focused on breast cancers that are classified as estrogen receptor positive (ER+). Although there are numerous neoadjuvant treatments for breast cancers that are not ER+, there are few neoadjuvant treatments for ER+ breast cancer which comprises about 78% of all breast cancers. We believe there is a compelling need for therapy with our Endoxifen in this setting. An estimated ten million women in the U.S. have mammographic breast density, or MBD, for which there is no FDA-approved treatment. MBD is an emerging public health issue and studies conducted by others have shown that MBD increases the risk of developing breast cancer and that reducing MBD can reduce the incidence of breast cancer. The American Cancer Society estimates that in the U.S. in 2022, 287,850 women will be diagnosed with breast cancer, 47,550 of which will be under the age of 50 and 43,250 of which will die from the disease.
    • On Feb. 28, Atossa announced their financial results for the fiscal quarter and fiscal year ended December 31, 2021 and provides an update on recent company developments. Dr. Steven Quay, Atossa’s President and Chief Executive Officer stated, “We continue to make significant progress on our Endoxifen and COVID-19 programs, with the continuation of enrollment of the Australian trial for AT-H201, as well as enrollment in our Swedish Endoxifen Phase 2 trial. We look forward to moving into the next milestones during 2022, and to providing updates on these developing therapies for urgent unmet patient needs. Further, our strong balance sheet will continue to facilitate our development plans as we not only execute on these trials but also explore additional options that could create significant shareholder value.” READ The Balance of the story
    • On Jan. 27, Atossa issued the annual letter from President and CEO Dr. Steven C. Quay to Atossa stockholders.  The letter Bega as follows: “The last two years have changed the face of public health and uncovered the urgency to develop products not only to prevent widely spread infectious diseases, but to treat them with the same level of focus and dedication applied to prevention. Despite the launch of highly efficacious vaccines during 2021, the toll that COVID-19 was taking on public health was not reduced. The rise of the Omicron variant toward the end of the year, and emerging long-term impact of long COVID, remain an important public health priority, and one that Atossa is dedicated to addressing. A key feature of the original SARS-CoV-2 virus, and that is retained in both the Delta and Omicron variants, is the furin cleavage site found on the Spike protein which facilitates viral infection. Our COVID-19 programs under development are designed to interact with this cleavage site so they are expected to be effective against both current and future COVID-19 variants that continue to contain a furin cleavage site. In the meantime, we are also very excited about the ongoing development of our breast health programs with our proprietary drug Endoxifen, with one Phase 2 study underway and another expected to commence in the next quarter. We raised over $110 million in capital in 2021 and we are well positioned to execute on our programs in 2022.” Click here to read the balance of the letter now.
    • On Jan. 18, Atossa announced it is advancing to enroll participants in Part B of its Phase 1/2a clinical study of AT-H201 in Australia, consisting of multiple ascending dose cohorts in healthy participants. The nebulized formulation, AT-H201, is being developed as an inhalation therapy for moderately to severely-ill hospitalized COVID-19 patients and for “long-haul” patients with post-infection pulmonary disease. Part A of the study, which consisted of a single ascending dose group of 4 cohorts of healthy participants, has now been completed. The Australian Human Research Ethics Committee has reviewed the safety data from Part A and has approved the study to proceed to Part B. “The results of the first part of the study were extremely encouraging and the ethics committee concluded we may now proceed to enroll the next group of participants,” said Steven Quay, M.D., Ph.D., Atossa’s CEO and President. “A record number of hospitalizations driven by the Omicron variant is producing a crisis at many healthcare facilities. Additional therapies to combat COVID-19 are desperately needed.” The Phase 1/2a placebo-controlled study will enroll a total of 60 healthy participants and moderately-ill hospitalized COVID-19 patients. The study has 4 parts: Part A – a single ascending dose part, Part B – a multiple ascending dose part, Part C – a combination part in healthy individuals, and Part D a combination in COVID-19 infected patients. The study is being conducted by Avance Clinical Pty Ltd., a leading Australian clinical research organization. AT-H201 is a proprietary combination of two drugs previously approved by the FDA to treat other diseases and by other administration routes. AT-H201 is intended to be inhaled via a nebulizer to improve compromised lung function for moderate to severely ill, hospitalized COVID-19 patients and for “long-haul” patients with post-infection pulmonary disease. In May 2020, we completed in vitro testing of AT-H201 which showed that the components of AT-H201 inhibit SARS-CoV-2 infectivity of VERO cells, which is a standard cell type being used to study infectivity of the coronavirus. The Phase 1/2a study in Australia and other clinical studies must be successfully completed and regulatory approvals must be obtained before AT-H201 may be commercialized. No assurance can be given than studies will be successful or that regulatory approvals will be obtained.
    • On Dec. 22, Atossa announced that it has initiated enrollment of its Phase 2 clinical study of oral Z-Endoxifen in Sweden. Participants in the study will be premenopausal women with elevated mammographic breast density, which is an emerging public health issue affecting more than 10 million women in the United States and many more worldwide. “This is an extremely important milestone as it marks the next phase of developing our proprietary Z-Endoxifen,” said Steven Quay, M.D., Ph.D., Atossa’s Chairman and CEO. “This study will help determine the relationship between daily doses of Endoxifen and reduction in breast density and will help us further assess safety and tolerability. We look forward to providing progress updates as they become available.” Physician-Scientist and CEO of Atossa, Steven Quay, MD, PhD, recently published an e-print on his research into a new coronavirus, named BANAL-236, reported by the Institut Pasteur in September 2021. At the time, BANAL-236 was the first bat coronavirus with high homology to SARS-CoV-2 that could directly infect human cells using the same receptor that SARS-CoV-2 uses. The new research reports that BANAL-236 has evolved the ability to infect human cells by an unknown mechanism that violates over 40 years of coronavirus research. The COVID-19 e-print is available here and has also been submitted to Nature. “When I read the paper from the Institut Pasteur and looked at the virus, I immediately assumed there was an error in either the way the sequence was assembled or a mix up in the lab with another virus to explain the infectivity,” Quay said. “I contacted the Institut Pasteur with my findings and was deeply disturbed to learn that there was not, in fact, some simple mistake had occurred to explain things. I now knew we were in uncharted waters with a virus that is missing eight key elements that have been shown, over 40 years of research, to be required for growth.”
    • Recently, Physician-Scientist and CEO of Atossa, Steven Quay, MD, PhD, published an e-print on his research into a new coronavirus, named BANAL-236, reported by the Institut Pasteur in September 2021. At the time, BANAL-236 was the first bat coronavirus with high homology to SARS-CoV-2 that could directly infect human cells using the same receptor that SARS-CoV-2 uses. The new research reports that BANAL-236 has evolved the ability to infect human cells by an unknown mechanism that violates over 40 years of coronavirus research. The COVID-19 e-print is available here and has also been submitted to Nature. “When I read the paper from the Institut Pasteur and looked at the virus, I immediately assumed there was an error in either the way the sequence was assembled or a mix up in the lab with another virus to explain the infectivity,” Quay said. “I contacted the Institut Pasteur with my findings and was deeply disturbed to learn that there was not, in fact, some simple mistake had occurred to explain things. I now knew we were in uncharted waters with a virus that is missing eight key elements that have been shown, over 40 years of research, to be required for growth.”
    • On Dec. 6, Atossa announced that it has completed a pre-investigational new drug (PIND) meeting with the FDA. The purpose of the meeting was to obtain input from the FDA on pre-clinical, clinical, manufacturing and regulatory matters in the U.S. for Atossa’s proprietary Z-endoxifen to treat breast cancer in the neoadjuvant (prior to surgery) setting. “Holding a PIND meeting is a critical milestone in the regulatory pathway,” said Dr. Heather Fraser, Atossa’s VP Clinical, Regulatory and CMC. “The feedback we received will be very helpful in preparing our request to the FDA to open an IND for a multi-center Phase 2 study to further advance our Z-endoxifen in the neoadjuvant setting. We plan to focus our development on pre-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer for whom the current treatment options typically include drugs that suppress ovarian function and essentially force the patient into menopause. We look forward to opening an IND in the second quarter of 2022 and then commencing a Phase 2 study in this setting. Despite the uncertainties and challenges created by the worldwide, COVID-19 pandemic in 2021, it is gratifying to be able to announce this major step forward for our proprietary Z-endoxifen program development in the U.S., the largest market for pharmaceuticals for the treatment of breast cancer,” said Dr. Steven Quay, Atossa’s President and Chief Executive Officer. “The guidance from this meeting with the FDA, together with the ongoing non-clinical studies with Z-endoxifen and the initiation of a technology transfer process to establish a commercial cGMP manufacturing supplier to support the further drug development and ultimate commercial launch of Z-endoxifen, will put Atossa in an excellent position to continue the development of Z-endoxifen in 2022.” Based in part on the feedback received from the FDA and subject to its approval, Atossa’s current plan, is to continue developing Z-endoxifen for the treatment of pre-menopausal women with ER+/HER2- breast cancer in the neoadjuvant setting. Atossa plans to apply to the FDA for an IND to conduct a Phase 2 study in the U.S. to compare Z-endoxifen to standard of care, which is typically ovarian functional suppression along with either an aromatase inhibitor or tamoxifen. Atossa also plans to conduct a pharmacokinetic run-in study as a part of the Phase 2 study to further define potential dose levels.
  •  


  • Shares INVO Bioscience (NASDAQ: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, closed at $1.66. 
    • On April 14, INVO Bioscience announced plans to open an INVO Center in Kansas City, Missouri. The Kansas City INVO Center will focus on patients in need of advanced fertility care utilizing the efficient, effective, and affordable INVOcell® solution. The Company currently has three operational INVO Centers treating patients in Birmingham, Alabama, Atlanta, Georgia, and Monterrey, Mexico, with others scheduled to open in the San Francisco and Tampa areas. The Company evaluates several criteria and data points as part of its efforts to identify markets suitable for INVO Centers. Based on an analysis of current population statistics, we believe that Kansas City may have upwards of 33,000 patients suffering with Infertility. With an estimated 1,500 IVF treatments annually, there exists a large gap of available care to treat local demand. Similar to other INVO Centers, the Company expects to engage physician partners to support its efforts in the Kansas City market.
 
  • Regained full U.S. commercialization rights to sell its INVOcell® solution directly into existing in vitro fertilization (IVF) clinics, to expand the number of U.S. INVO Centers free of any limitations, and to pursue its market expansion strategy focused on increasing access to care and democratizing fertility care for the underserved patient population.
  • Opened three INVO Center’s in 2021, including Birmingham, Alabama, Atlanta, Georgia, and Monterrey, Mexico with another clinic scheduled to open in the San Francisco area. The Company recently identified Tampa, Florida as the location of the next INVO Center.
  • Entered into an agreement with Ovo in Spain to expand INVOcell® commercialization in all four of their Ovoclinics, establish a European center of excellence and training site for INVOcell® and the IVC procedure, and leverage Ovobank’s fertility clinic relationships across Europe.
  • Completed the acquisition of a Canadian-based entity, originally formed to offer INVOcell®, to advance distribution efforts in Canada, where the product is already approved by Health Canada and cleared for importing.
  • Obtained regulatory approval to commercialize INVOcell® in Thailand and Nigeria.
  • Presented four poster abstracts discussing INVOcell® at the 77th Scientific Congress & Expo of the American Society for Reproductive Medicine held in Baltimore, Maryland in October 2021.
  • Revenue was $4.2 million for the year ended December 31, 2021, including $2.9 million due to the accelerated recognition of deferred revenue from the Ferring license, and compared to $1.0 million for the previous year.
  • Adjusted EBITDA for 2021 was $(2.8) million, which included a $0.7 million loss attributable to the Company’s joint ventures, compared to $(3.7) million in the prior year (see Adjusted EBITDA Table).

Steve Shum, CEO of INVO stated, “2021 was an exciting year for INVO as we opened our first INVO Center clinics. Our INVO Center model represents a strategy aimed at expanding adoption of INVOcell® and allowing us to capture a significantly larger percentage of the per-cycle IVC procedure revenue it enables. The INVO Centers are designed to offer attractive economics for our shareholders, medical practitioner partners and patients, and we believe are key to our efforts to address the fertility industry’s biggest challenges of cost and capacity. In addition to our announced plans to open additional centers in the San Francisco Bay Area and Tampa, Florida, we are evaluating over 20 additional US locations which represent attractive opportunities to open new INVO Centers. We also are in discussions for similar ventures across the globe. On the distribution side of our business, during the first quarter of 2022, we began selling directly to existing IVF fertility clinics in the U.S., after regaining full domestic commercialization rights to the INVOcell® upon termination of our prior agreements with Ferring. We are also seeing increased distribution activity from some of our partners in Europe and Africa. We are enthusiastic about our multi-channel strategy of supporting, servicing, and expanding across existing IVF clinic networks and building new, dedicated INVO Centers. We expect this strategy to drive increased market awareness and utilization of our revolutionary technology, and provide an affordable and equally effective fertility treatment alternative to the large, underserved patient population.”

 
    • INVO Bioscience exhibited at the INVOcell solution at the 2022 Pacific Coast Reproductive Society (PCRS) Annual Meeting, taking place March 23-27 at the Renaissance Esmeralda Resort & Spa in Indian Wells, CA. Chris Myer, INVO’s Senior VP, Business Development, Americas, and Bojan (Bo) Mitrovic, PhD, INVO’s Director, Sales, US will both be available in Booth #314 discussing INVOcell with the broader Assisted Reproductive Technology (ART) physician community.
      Steve Shum, CEO of INVO Bioscience, commented, “A key component to our go forward commercialization strategy is to synchronize and take an expanded, more comprehensive and direct approach toward our U.S. efforts. PCRS provides us an opportunity to easily connect with a number of U.S. IVF clinics that have already trained on the INVOcell device and the IVC treatment process, as well as introduce our solution to additional clinic operators interested in expanding their treatment options and overall capacity by introducing INVOcell to patients.” Pacific Coast Reproductive Society is a multidisciplinary medical specialty society providing Continuing Medical Education (CME) to physicians and allied healthcare professionals. The PCRS Annual Meeting provides an outstanding forum for the exchange of information and the advancement of the ideologies of reproductive medicine in a relaxed and collegial setting. Session topics have been carefully selected to bring you the highest quality, innovative CME, designed and presented by thought leaders in reproductive medicine.
  •  


  • Shares of NeuBase Therapeutics (NASDAQ: NBSE), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, closed at $1.44, -11.66% over the last 5-days. 
    • On March 16 and March 17, newly appointed Neubase CFO purchased a 10,000 shares of NBSE stock each day for a total of 20,000 shares at $1.62/share and $1.74/share respectively. Here’s the Form 4 filing at the SEC
    • On March 13, Neubase announced new preclinical data for its lead development candidate, NT-0231.F, to treat myotonic dystrophy type 1 (DM1). These data are being presented in poster and oral presentations at the 2022 MDA Clinical & Scientific Conference, which is taking place virtually and in-person in Nashville, Tennessee from March 13-16, 2022. These data was presented at the RNA Leaders World Congress in Basel on March 17th. 
       
      Sandra Rojas-Caro, M.D., Chief Medical Officer of NeuBase, said, “DM1 is a significant unmet medical need characterized by myotonia, muscle weakness and wasting, and cognitive impairments. We are excited to present new preclinical data for our lead candidate, NT-0231.F, to support our differentiated approach for DM1. Systemic administration of NT-0231.F achieves clinically relevant molecular and functional rescue in the muscle in the HSALR model, which reproduces many components of the disease. Initial pharmacokinetic data supports a whole-body solution to the disease, and additional preclinical work is in progress to assess biodistribution in key tissues. These data are an important milestone in our DM1 development program and support our pursuit of a best-in-class therapeutic profile for the disease.”
       
      A single intramuscular dose confirmed that NT-0231.F is pharmacologically active in the muscle and drives molecular and functional rescue in the HSALR model, including splice rescue, nuclear aggregate resolution, and myotonia (delayed muscle relaxation after contraction) reversal. A single intravenous (IV) dose of NT-0231.F or multiple subcutaneous (SC) doses over a 28-day period broadly rescued splicing, including the chloride channel (Clcn1) transcript, and reversed myotonia in the model. A single IV dose of NT-0231.F provides initial splice rescue at around two weeks, with significant splice rescue around three weeks. Myotonia reversal was achieved at around four weeks, with effects enduring to at least six weeks, the longest time point tested so far. A time course of multiple SC doses across increasing concentrations of NT-0231.F was also investigated and showed splice rescue and myotonia reversal in a dose-responsive manner, illustrating feasibility of the differentiated and patient-friendly SC route. In pharmacokinetic studies of NT-0231.F in wild-type BALB/C mice, a single IV or SC dose showed high volume of distribution, suggesting wide tissue distribution. 
       
      Dietrich A. Stephan, Ph.D., Founder, Chief Executive Officer, and Chairman of NeuBase, said, “We now have preclinical data in the gold-standard animal model for our development candidate demonstrating robust reversal of myotonia, as measured by muscle relaxation in these studies. We believe we are the only company that has shown improved muscle relaxation after systemic routes of administration. The HSALR model is also a high bar for human disease in that it contains at least 10x more mutant gene CUG- repeat targets than patients, giving us further conviction in the robustness of our approach. Not only does this data support the further advancement of our lead program in DM1 and keep us on track for submitting an Investigational New Drug application to the U.S. Food and Drug Administration in 4Q CY2022, it also validates that we can utilize our PATrOLTM platform to design novel genetic medicines that target and rescue many other gene dysfunctions, with the potential for clinically impactful outcomes in both rare and common diseases.”
    • On Feb. 28,  Neubase announced that new preclinical data from its myotonic dystrophy type 1 (DM1) program will be featured in presentations at the 2022 MDA Clinical & Scientific Conference. MDA 2022 will be taking place virtually and in-person in Nashville, Tennessee, from March 13-16, 2022, and the abstracts will be available on the meeting website. Expanding upon initial data presented in June 2021, the presentations will include new data of a PATrOL™-enabled investigational genetic therapy for DM1. NeuBase will present molecular and functional pharmacological activity of its DM1 investigational genetic therapy in the HSALR mouse model following single and repeated subcutaneous, intravenous, and intramuscular administration. The HSALR model carry the long repeat (LR) length of the DMPK repeat expansion and recapitulates many aspects of the clinical presentation of DM1. Additional pharmacokinetic data will be presented of NeuBase’s DM1 investigational genetic therapy in wild-type mice demonstrating distribution and pharmacologic activity throughout the body, including the brain and muscle, following systemic administration. Patients with DM1 suffer from cognitive deficits and muscle pathology caused by a trinucleotide expansion in the DMPK gene. NeuBase’s DM1 investigational genetic therapy targets DMPK pre-mRNA with a novel peptide-nucleic acid (PNA) pharmacophore and is designed to selectively engage with the toxic RNA hairpin structure and release the splicing proteins to restore RNA splicing and downstream protein production. The PNA pharmacophore is conjugated to NeuBase’s novel delivery technology that is designed for broad distribution, including into the deep brain, with the potential for a whole body, disease-modifying solution for DM1.
    • On Feb. 10, NeuBase reported its financial results for the three-month period ended December 31, 2021, and other recent developments. Dietrich A. Stephan, Ph.D., Founder, Chief Executive Officer, and Chairman of NeuBase stated,  “We are making significant progress in advancing the IND-enabling studies for the development candidate for our myotonic dystrophy type 1 (DM1) program, and we expect to file an IND with the FDA in Q4 CY2022. These studies are on track for data readouts to occur throughout CY2022, with the first presentation of rodent pharmacokinetic and bioavailability data to occur at an upcoming scientific meeting. We expect these data to illustrate the differentiated potential for our candidate to be a whole-body solution to treat DM1 and the unique ability of our delivery shuttle for distribution into the brain. The ability to cross the blood brain barrier and reach the deep brain is also especially relevant for our Huntington’s disease program, where we are planning to initiate scale-up and toxicology activities this year. In addition, I’m especially excited to have welcomed Todd to the executive team as Chief Financial Officer. The team and science are strong, and I believe we are at a pivotal moment for NeuBase as we are building a robust data package that is expected to support bringing our first candidate into the clinic for DM1, validate our genetic medicine technology platform to efficiently deliver genetic medicines with broad tissue distribution, including into the deep brain, and to precisely engage genetic mutations in a manner that is well-tolerated with the potential for sustained efficacy.” READ THE BALANCE OF THE RELEASE HERE. 
 

Dietrich A. Stephan, Ph.D, CEO, & Founder of NeuBase Therapeutics (NASDAQ: NBSE)

    • On February 3rd, our sister organization, Tribe Public hosted a Webinar Presentation and Q&A Event titled “Drugging The Genome.” The event was co-hosted by Dietrich A. Stephan, Ph.D, CEO, & Founder of NeuBase Therapeutics (NASDAQ: NBSE). The event video may now be viewed at the Tribe Public YouTube Channel at this link
  •  
    • On Jan. 10, NeuBase announced  the appointment of Todd P. Branning as Chief Financial Officer (CFO). Mr. Branning has more than 25 years of experience leading corporate finance and accounting, tax, financial planning and analysis, and investor relations for several publicly traded pharmaceutical companies. Prior to joining NeuBase, Mr. Branning was CFO of Phathom Pharmaceuticals, Inc., a publicly traded late clinical-stage biopharmaceutical company. Before that, he was Senior Vice President, CFO of Amneal Pharmaceuticals, Inc., a publicly traded pharmaceutical company, where he helped to build, leverage, and optimize infrastructure following the completion of a transformational merger. Prior to joining Amneal, he was Senior Vice President, CFO of the global generic medicines division at Teva Pharmaceutical Industries Ltd., a multinational generic pharmaceuticals company, where he led the finance function and served on the leadership team responsible for managing the day-to-day operations of Teva’s largest multi-billion-dollar commercial unit. Mr. Branning has also held financial leadership roles at Allergan plc, PricewaterhouseCoopers LLP, PPG Industries, Inc., and Merck & Co., Inc. Mr. Branning received his BBA from the University of Miami and MBA from Carnegie Mellon University. Mr. Branning is also a Certified Public Accountant and has completed a CFO certification program at The Wharton School at the University of Pennsylvania.
  •  


Thanks again for your attention this week. Please continue to share your thoughts, questions, & ideas as we move forward. 

In the meantime, please enjoy the balance of the weekly newsletter’s videos, quotes, updates and let’s find ways to crush it again this year!

Investing & Inspiration

  1. “We know what we are, but know not what we may be.” – William Shakespeare
  2. “Our life always expresses the result of our dominant thoughts.” – Soren Kierkegaard

  3. Attitude determines the altitude of life.” – Edwin Louis Cole

  4. “Don’t go through life, grow through life.” – Eric Butterworth
  5. “Life is too short for long-term grudges.” – Elon Musk
  6. There cannot be a crisis next week. My schedule is already full.” – Henry Kissinger
  7. “Success consists of getting up just one more time than you fall.” – Oliver Goldsmith
  8. “The Earth is the cradle of humanity, but mankind cannot stay in the cradle forever.” – Konstantin Tsiolkovsky
  9. “Ours is a world of nuclear giants and ethical infants. We know more about war that we know about peace, more about killing that we know about living.” – Omar N. Bradley
  10. “Beauty surrounds us, but usually we need to be walking in a garden to know it.” – Rumi
  11. “But man is not made for defeat. A man can be destroyed but not defeated.” – Ernest Hemingway
  12. “Don’t watch the clock; do what it does. Keep going.” – Sam Levenson
  13. “Let there be work, bread, water and salt for all.” – Nelson Mandela
  14. “The social object of skilled investment should be to defeat the dark forces of time and ignorance which envelope our future.” – John Maynard Keynes
  15. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  16. I know not with what weapons World War III will be fought, but World War IV will be fought with sticks and stones. – Albert Einstein
  17. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
  18. “If you can’t describe what you are doing as a process, you don’t know what you’re doing.” – W. Edwards Deming
  19. “Never interrupt your enemy when he is making a mistake.” – Napoleon Bonaparte
  20. “Be sure you put your feet in the right place, then stand firm.” – Abraham Lincoln
  21. Without investment there will not be growth, and without growth there will not be employment.” – Muhtar Kent
  22. “You have to do your own growing no matter how tall your grandfather was.” – Abraham Lincoln
  23. “Victory has a thousand fathers, but defeat is an orphan.” – John F. Kennedy
  24. “Delete the negative; accentuate the positive!” – Donna Karan
  25. “It’s crazy how fast time flies and how things progress.” – Nathan Chen
  26. The world is a dangerous place to live; not because of the people who are evil, but because of the people who don’t do anything about it.” – Albert Einstein
  27. “Life isn’t about finding yourself. Life is about creating yourself.” – George Bernard Shaw
  28. “Everything has beauty, but not everyone sees it.” – Confucius
  29. A man must be big enough to admit his mistakes, smart enough to profit from them, and strong enough to correct them.” – John C. Maxwell
  30. “Walking with a friend in the dark is better than walking alone in the light.” – Helen Keller
  31. “A man who dares to waste one hour of time has not discovered the value of life.” – Charles Darwin
  32. “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
  33. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  34. “I like to encourage people to realize that any action is a good action if it’s proactive and there is positive intent behind it.” – Michael J. Fox

  35. “Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn

  36. “But investment in space stimulates society, it stimulates it economically, it stimulates it intellectually, and it gives us all passion.” – Bill Nye

  37. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  38. “Life is a tragedy when seen in close-up, but a comedy in long-shot.” – Charlie Chaplin
  39. No matter what you’re going through, there’s a light at the end of the tunnel and it may seem hard to get to it but you can do it and just keep working towards it and you’ll find the positive side of things.” – Demi Lovato
  40. “Infrastructure investment in science is an investment in jobs, in health, in economic growth and environmental solutions.” – Oren Etzioni
  41. “Educating our children and giving them the skills they need to compete in a global economy is a smart investment in our country’s future.” – Sheldon Whitehouse
  42. “Know thy self, know thy enemy. A thousand battles, a thousand victories.” – Sun Tzu
  43. If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
  44. “Beware of missing chances; otherwise it may be altogether too late some day.” – Franz Liszt
  45. “The sofa is a really important investment for anybody, and I don’t mean financially. You need to find a really great sofa that can transition with you, and you can build from there.” – Jeremiah Brent
  46. “There is no investment you can make which will pay you so well as the effort to scatter sunshine and good cheer through your establishment.” – Orison Swett Marden
  47. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
  48. There is little that can withstand a man who can conquer himself.” – Louis XIV
  49. “In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
  50. “A camel makes an elephant feel like a jet plane.” – Jackie Kennedy
  51. “The advance of technology is based on making it fit in so that you don’t really even notice it, so it’s part of everyday life.” – Bill Gates
  52. “Success depends upon previous preparation, and without such preparation there is sure to be failure.” – Confucius
  53. “Coming together is a beginning; keeping together is progress; working together is success.” – Edward Everett Hale
  54. “Never do anything against conscience even if the state demands it.”– Albert Einstein
  55. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
  56. “The true measure of a man is how he treats someone who can do him absolutely no good.” – Samuel Johnson
  57. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
  58. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  59. “The best preparation for tomorrow is doing your best today.” – H. Jackson Brown, Jr.
  60. “Friendship marks a life even more deeply than love. Love risks degenerating into obsession, friendship is never anything but sharing.” – Elie Wiesel
  61. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” – Liya Kebede
  62. “Success isn’t measured by money or power or social rank. Success is measured by your discipline and inner peace.” – Mike Ditka
  63. “No matter how many goals you have achieved, you must set your sights on a higher one.” – Jessica Savitch
  64. “Start where you are. Use what you have. Do what you can.”– Arthur Ashe
  65. “The secret of getting ahead is getting started.” – Mark Twain
  66. “The amount of work and the amount of both physical and emotional investment it takes to get to the top.” – Drew Bledsoe
  67. “The true measure of a man is how he treats someone who can do him absolutely no good.” – Samuel Johnson
  68. “If a man does not keep pace with his companions, perhaps it is because he hears a different drummer. Let him step to the music which he hears, however measured or far away.” – Henry David Thoreau
  69. “Adopting the right attitude can convert a negative stress into a positive one.” – Hans Selye
  70. “Money is something that keeps you alive and healthy and just keeps you focused. It’s the drive. It’s the passion.” – Travis Scott
  71. “Common sense is the collection of prejudices acquired by age eighteen.” – Albert Einstein
  72. “Live life to the fullest, and focus on the positive.” – Matt Cameron
  73. “You cannot escape the responsibility of tomorrow by evading it today.” – Abraham Lincoln
  74. “However difficult life may seem, there is always something you can do and succeed at.”– Stephen Hawking
  75. “Once you bring life into the world, you must protect it. We must protect it by changing the world.” – Elie Wiesel
  76. “Don’t let your ego get too close to your position, so that if your position gets shot down, your ego doesn’t go with it.” – Colin Powell
  77. “Good things do not come easy. The road is lined with pitfalls.” – Desi Arnaz
  78. Honoring the sacrifices many have made for our country in the name of freedom and democracy is the very foundation of Veterans Day.” – Charles B. Rangel,
  79. “The true sign of intelligence is not knowledge but imagination.” – Albert Einstein
  80. “Trust yourself, you know more than you think you do.” – Benjamin Spock
  81. “This idea of mutual appreciation and partnerships and investment in our people is very important to me and will continue to be important.” – Dennis Muilenburg
  82. “The true secret of happiness lies in taking a genuine interest in all the details of daily life.” – William Morris
  83. “Formal education will make you a living; self-education will make you a fortune.” – Jim Rohn
  84. “Give me the luxuries of life and I will willingly do without the necessities.” – Frank Lloyd Wright
  85. “If opportunity doesn’t knock, build a door.” – Milton Berle
  86. “Age is an issue of mind over matter. If you don’t mind, it doesn’t matter.” – Mark Twain
  87. “The smallest deed is better than the greatest intention.” – John Burroughs
  88. “It’s the steady, quiet, plodding ones who win in the lifelong race.” – Robert W. Service
  89. “When I was young I thought that money was the most important thing in life; now that I am old I know that it is.” – Oscar Wilde
  90. “A savvy entrepreneur will not always look for investment money, first.” – Daymond John
  91. “In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
  92. “Look deep into nature, and then you will understand everything better.” -Albert Einstein

  93. “The young man knows the rules, but the old man knows the exceptions.” – Oliver Wendell Holmes, Sr.

  94. “Don’t go through life, grow through life.”– Eric Butterworth
  95. “This life is worth living, we can say, since it is what we make it.” – William James
  96. “People who think they know everything are a great annoyance to those of us who do.” –  Isaac Asimov
  97. “True life is lived when tiny changes occur.”  – Leo Tolstoy
  98. “If you want a guarantee, buy a toaster.” – Clint Eastwood
  99. “In order to attain the impossible, one must attempt the absurd.” – Miguel de Cervantes
  100. “Aim for the moon. If you miss, you may hit a star.” – W. Clement Stone
  101. “If I had to live my life again, I’d make the same mistakes, only sooner.” – Tallulah Bankhead
  102. “The deal machinations many companies put themselves through, while certainly a bonanza for investment bankers, can confound the typical investor.” – Whitney Tilson
  103. “Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn
  104. “Procrastination is the art of keeping up with yesterday.” – Don Marquis
  105. “Do not fear mistakes. You will know failure. Continue to reach out.” – Benjamin Franklin

  106. “Success is peace of mind which is a direct result of self-satisfaction in knowing you did your best to become the best you are capable of becoming.” – John Wooden
  107. “One fails forward toward success.” – Charles Kettering
  108. “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
  109. “I hear and I forget. I see and I remember. I do and I understand.” – Confucius
  110. “I’m a very strong believer in listening and learning from others.” – Ruth Bader Ginsburg
  111. “Blessed are those who give without remembering and take without forgetting.” – Elizabeth Bibesco
  112. “As you walk down the fairway of life you must smell the roses, for you only get to play one round.” – Ben Hogan
  113. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  114. “Economics is all about consumption. People either spend money now or they use financial instruments – like bonds, stocks and savings accounts – so they can spend more later.” – Adam Davidson
  115. “Ever tried. Ever failed. No matter. Try Again. Fail again. Fail better.” -Samuel Beckett
  116. “In the post-industrial economy, ideas and great minds often provide far greater return on investment than any other resources or capital investments.” – Marvin Ammori
  117. “Work like you don’t need the money. Love like you’ve never been hurt. Dance like nobody’s watching.” – Satchel Paige
  118. “One of the rules I’ve learned is that struggling to try and think your way into making an investment is usually the best way to not have a great outcome.” – Stephen A. Schwarzman
  119. “The secret of business is to know something that nobody else knows.” – Aristotle Onassis
  120. “It takes a long time to grow an old friend.” – John Leonard
  121. “Life is a dream for the wise, a game for the fool, a comedy for the rich, a tragedy for the poor.”– Sholom Aleichem
  122. “The truth is you don’t know what is going to happen tomorrow. Life is a crazy ride, and nothing is guaranteed.” – Eminem
  123. “Man is only great when he acts from passion.” – Benjamin Disraeli
  124. “We need to stop thinking about infrastructure as an economic stimulant and start thinking about it as a strategy. Economic stimulants produce Bridges to Nowhere. Strategic investment in infrastructure produces a foundation for long-term growth.” – Roger McNamee
  125. “We must let go of the life we have planned, so as to accept the one that is waiting for us.” – Joseph Campbell
  126. “Put your heart, mind, and soul into even your smallest acts. This is the secret of success.” – Swami Sivananda
  127. “I can’t change the direction of the wind, but I can adjust my sails to always reach my destination.” – Jimmy Dean
  128. “Companies have too many experts who block innovation. True innovation really comes from perpendicular thinking.” – Peter Diamandis
  129. “By failing to prepare, you are preparing to fail.” – Benjamin Franklin
  130. “We cannot solve our problems with the same thinking we used when we created them.” – Albert Einstein
  131. “When you’re an investor, you can look at the quantitative and qualitative elements of an investment, but there’s a third aspect: What you feel in your gut.” – Kevin O’Leary
  132. “Set your course by the stars, not by the lights of every passing ship.” – Omar N. Bradley
  133. “Do not take life too seriously. You will never get out of it alive.” – Elbert Hubbard
  134. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey 
  135. “Every good painter paints what he is.” – Jackson Pollock
  136. “If you believe in yourself and have dedication and pride – and never quit, you’ll be a winner. The price of victory is high but so are the rewards.” – Bear Bryant
  137. “Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
  138. “You cannot have a positive life and a negative mind.” – Joyce Meyer 
  139. “Like wildebeest and zebra migration across the Serengeti, investment managers and consultants, too, have a habit of running together and, every now and then, changing direction.” – Sanjaya Baru
  140. “If people are anything but enthusiastic about the information or ideas that they’re sharing, they’re either not that invested in what they’re doing – or they’re not communicating that investment effectively.” – Ana Kasparian 
  141. “Life consists not in holding good cards but in playing those you hold well.” – Josh Billings 
  142. “Friend, there’s no greater investment in life than in being a people builder. Relationships are more important than our accomplishments.” – Joel Osteen
  143. “It’s only natural that the heavy users help contribute to the investment to keep the Web healthy. That is the most important concept of net neutrality.” – Lowell McAdam
  144. “The more sand that has escaped from the hourglass of our life, the clearer we should see through it.” – Jean Paul 
  145. “Eliminate emotion from your investment program.” -John C. Bogle

  146. “Modern medical advances have helped millions of people live longer, healthier lives. We owe these improvements to decades of investment in medical research.” – Ike Skelton
  147. “In every investment, before I get involved or invest, I always see what the mindset of the founder, the CEO, is.” – Zaza Pachulia
  148. “An investment said to have an 80% chance of success sounds far more attractive than one with a 20% chance of failure. The mind can’t easily recognize that they are the same.” – Daniel Kahneman
  149. “The return on investment in global health is tremendous, and the biggest bang for the buck comes from vaccines. Vaccines are among the most successful and cost-effective health investments in history.” – Seth Berkley
  150. “Few things in the world are more powerful than a positive push. A smile. A world of optimism and hope. A ‘you can do it’ when things are tough.” – Richard M. DeVos
  151. “To be yourself in a world that is constantly trying to make you something else is the greatest accomplishment.” – Ralph Waldo Emerson
  152. “We all have dreams. But in order to make dreams come into reality, it takes an awful lot of determination, dedication, self-discipline, and effort.”  – Jesse Owens
  153. “The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward- American Writer, Born 1921
  154. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
  155. “The secret of your future is hidden in your daily routine.” – Mike Murdock
  156.  “If somebody puts you down or criticizes you, just keep on believing in yourself and turn it into something positive.” – Leah LaBelle
  157. “Opportunity is missed by most people because it is dressed in overalls and looks like work”. -Thomas A. Edison
  158. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
  159. “Human behavior flows from three main sources: desire, emotion, and knowledge.” – Plato

  160. “We are what our thoughts have made us; so take care about what you think. Words are secondary. Thoughts live; they travel far.” – Swami Vivekananda
  161. “Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill
  162. “If you don’t know where you are going, any road will get you there.” – Lewis Carroll

  163. “Don’t worry about being a star, worry about doing good work, and all that will come to you.” – Ice Cube

  164. “It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare

  165. Prediction is very difficult, especially if it’s about the future.” – Niels Bohr (Danish Physicist)
  166. “It is indeed true that the stock market can forecast the business cycle.” -Paul Samuelson

  167. “The wisest rule in investment is: when others are selling, buy. When others are buying, sell. Usually, of course, we do the opposite. When everyone else is buying, we assume they know something we don’t, so we buy. Then people start selling, panic sets in, and we sell too.” – Jonathan Sacks

  168. “What lies behind you and what lies in front of you, pales in comparison to what lies inside of you.” – Ralph Waldo Emerson
  169. “Each new generation born is in effect an invasion of civilization by little barbarians, who must be civilized before it is too late.” – Thomas Sowell
  170. “Life is 10% what happens to you and 90% how you react to it.” – Charles R. Swindoll
  171. “The truth is you don’t know what is going to happen tomorrow. Life is a crazy ride, and nothing is guaranteed.” – Eminem
  172. “View health as an investment, not an expense.” – John Quelch

  173. “Opportunity does not knock, it presents itself when you beat down the door.” – Kyle Chandler

  174. “If you don’t know where you are going, any road will get you there.” – Lewis Carroll
  175. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
  176. “That which does not kill us makes us stronger.” – Friedrich Nietzsche
  177. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
  178. “A problem is a chance for you to do your best.”–  Duke Ellington
  179. “The best way to predict the future is to create it.” -Peter Drucker
  180. “I’m involved in the stock market, which is fun and, sometimes, very painful.” – Regis Philbin
  181. “Who owns the future? This is the question at the heart of every stock market.” – John Landgraf
  182. “One of the funny things about the stock market is that every time one person buys, another sells, and both think they are astute.” – William Feather
  183. While I’m sure some millennials are concerned with the ethical issues involved in mining for diamonds, the main reason they steer clear of the gems is because, well, they’re a dumb investment.” – Ana Kasparian
  184. “The wisest rule in investment is: when others are selling, buy. When others are buying, sell. Usually, of course, we do the opposite. When everyone else is buying, we assume they know something we don’t, so we buy. Then people start selling, panic sets in, and we sell too.” – Jonathan Sack
  185. “We must shift our thinking away from short-term gain toward long-term investment and sustainability, and always have the next generations in mind with every decision we make.” –  Deb Haaland
  186. “The only way to have a friend is to be one.” –  Ralph Waldo Emerson
  187. “If you believe in yourself and have dedication and pride – and never quit, you’ll be a winner. The price of victory is high but so are the rewards.” – Bear Bryant
  188. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” -Liya Kebede

  189. “Success is not final, failure is not fatal: it is the courage to continue that counts.”– Winston Churchill
  190. “Our greatest glory is not in never falling, but in rising every time we fall.” – Confucius

  191. “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes
  192. “Who controls the past controls the future. Who controls the present controls the past.” – George Orwell
  193. “If you get up in the morning and think the future is going to be better, it is a bright day. Otherwise, it’s not.” – Elon Musk
  194. “The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward
  195. “Start where you are. Use what you have. Do what you can.” – Arthur Ashe
  196. “Netflix, Amazon, iTunes – whatever platforms emerge – we are looking at as having the same potential that home video had for the movie business. Which means there are entirely new opportunities to monetize our capital investment in content and do so in ways that work for distributors, for consumers and for creators.” – Bob Iger
  197. “When you have no one to answer to, vendetta as investment strategy is as legitimate as anything.” – Carl Icahn

  198. “No other investment yields as great a return as the investment in education. An educated workforce is the foundation of every community and the future of every economy.” – Brad Henry
  199. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
  200. “Modern medical advances have helped millions of people live longer, healthier lives.

  201. We owe these improvements to decades of investment in medical research.”– Ike Skelton

  202. “Stock market goes up or down, and you can’t adjust your portfolio based on the whims of the market, so you have to have a strategy in a position and stay true to that strategy and not pay attention to noise that could surround any particular investment.” – John Paulson

  203. “Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
  204. “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
  205. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  206. “I think you have to learn that there’s a company behind every stock and there’s only one real reason why stocks go up. Companies go from doing poorly to doing well or small companies grow to large companies.” – Peter Lynch
  207. “Historically, there has been a bull market in the commodities every 20 or 30 years.” – Jim Rogers
  208. “The markets generally are unpredictable, so that one has to have different scenarios. The idea that you can actually predict what’s going to happen contradicts my way of looking at the market.” – George Soros
  209. “Stop trying to predict the direction of the stock market, the economy or the elections.” – Warren Buffett
  210. “An important key to investing is to remember that stocks are not lottery tickets.” – Peter Lynch
  211. “Learn everyday, but especially from the experiences of others. It’s cheaper!” – John Bogle
  212. “When purchasing depressed stock in troubled companies, seek out the ones with the superior financial positions and avoid the ones with loads of bank debt.” – Peter Lynch
  213. “No stock price is too low for bears or too high for bulls.” – John F. Heerdink, Jr.
  214. “Investment is most successful when it is most businesslike.” – Ben Graham

  215. “Value stocks are about as exciting as watching grass grow, but have you ever noticed just how much your grass grows in a week?” – Christopher Browne

  216. “Even the intelligent investor is likely to need considerable willpower to keep from following the crowd.” – Benjamin Graham
  217. “Individual who cannot master their emotions are ill-suited to profit from the investment process.” – Benjamin Graham
  218. “I made my first investment at age eleven. I was wasting my life until then.” – Warren Buffet
  219. “I don’t look to jump over seven-foot bars; I look around for one-foot bars that I can step over.” — Warren Buffett
  220. “There are only three measurements that tell you nearly everything you need to know about your organization’s overall performance: employee engagement, customer satisfaction, and cash flow. It goes without saying that no company, small or large, can win over the long run without energized employees who believe in the mission and understand how to achieve it.” – Jack Welch, former CEO of GE
  221. “Opportunities come infrequently. When it rains gold, put out the bucket, not the thimble” ― Warren Buffett
  222. “If you buy things you do not need, soon you will have to sell things you need.” – Warren Buffet
  223. “How many millionaires do you know who have become wealthy by investing in savings accounts? I rest my case.” — Robert G. Allen
  224. “It’s far better to buy a wonderful company at a fair price, than a fair company at a wonderful price.” – Warren Buffett
  225. “A market downturn doesn’t bother us. It is an opportunity to increase our ownership of great companies with great management at good prices.” — Warren Buffett
  226. “Every once in a while, the market does something so stupid it takes your breath away.” — Jim Cramer
  227. “The person who starts simply with the idea of getting rich won’t succeed; you must have a larger ambition.” — John D. Rockefeller
  228. “Know what you own, and know why you own it.” – Peter Lynch
  229. “Although it’s easy to forget sometimes, a share is not a lottery ticket… it’s part ownership of a business.” – Peter Lynch
  230. “Wise spending is part of wise investing. And it’s never too late to start.” – Rhonda Katz
  231. “Invest for the long haul. Don’t get too greedy and don’t get too scared.” – Shelby M.C. Davis

  232. “Fear incites human action far more urgently than does the impressive weight of historical evidence.”
    -Jeremy Siegel
  233. “With a good perspective on history, we can have a better understanding of the past and present, and thus a clear vision of the future.” — Carlos Slim Helu
  234. “If we like a business, we’re going to buy as much of it as we can and keep it as long as we can. And when we change our mind, we don’t take half measures.” – Warren Buffett
  235. “The most contrarian thing of all is not to oppose the crowd but to think for yourself.” — Peter Thiel

  236. “Never depend on a single income, make an investment to create a second source.” Warren Buffet

  237. Games are won by players who focus on the playing field –- not by those whose eyes are glued to the scoreboard.”
    ― Warren Buffett
  238. “The key to making money in stocks is not to get scared out of them.” – Peter Lynch
  239. “Courage taught me no matter how bad a crisis gets … any sound investment will eventually pay off.” — Carlos Slim Helu
  240. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  241. “As time goes on, I get more and more convinced that the right method of investment is to put fairly large sums into enterprises which one thinks one knows something about and in the management of which one thoroughly believes.” — John Maynard Keynes
  242. “Given a 10% chance of a 100 times payoff, you should take that bet every time.” — Jeff Bezos
  243. “Money is always eager and ready to work for anyone who is ready to employ it.” ― Idowu Koyenikan
  244. The secret to investing is to figure out the value of something – and then pay a lot less.” – Joel Greenblatt
  245. “We don’t have an analytical advantage, we just look in the right place.” – Seth Klarman
  246. “Men, it has been well said, think in herds. It will be seen that they go mad in herds, while they only recover their senses slowly, and one by one.” – Charles Mackay
  247. “It’s not whether you’re right or wrong that’s important, but how much money you make when you’re right and how much you lose when you’re wrong.” – George Soros
  248. “No Price is too low for a bear or too high for a bull.” — Anonymous
  249. “Investment is an asset or item that is purchased with the hope that it will generate income or appreciate in the future.” Anonymous
  250. “Behind every stock is a company. Find out what it’s doing.” — Peter Lynch
  251. “Wise spending is part of wise investing. And it’s never too late to start.” –Rhonda Katz
  252. “It amazes me how people are often more willing to act based on little or no data than to use data that is a challenge to assemble.” ― Robert Shiller
  253. “A bull market is like sex. It feels best just before it ends.” — Barton Biggs
  254. “The investor’s chief problem — even his worst enemy — is likely to be himself.” — Benjamin Graham
  255. “No profession requires more hard work, intelligence, patience, and mental discipline than successful speculation.” – Robert Rhea
  256. “Money is like a sixth sense – and you can’t make use of the other five without it.” – William Somerset Maugham
  257. “Compound interest is the eighth wonder of the world. He who understands it, earns it. He who doesn’t, pays it.” — Albert Einstein
  258. “Never count on making a good sale. Have the purchase price be so attractive that even a mediocre sale gives good results” — Warren Buffett
  259. “The stock market is a device for transferring money from the impatient to the patient.” – Warren Buffett
  260. “Thousands of experts study overbought indicators, head-and-shoulder patterns, put-call ratios, the Fed’s policy on money supply…and they can’t predict markets with any useful consistency, any more than the gizzard squeezers could tell the Roman emperors when the Huns would attack.” – Peter Lynch
  261. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  262. “You cannot save time for your future use however you can invest time for your future.” – John F. Heerdink, Jr. 
  263. “Know what you own, and know why you own it.” – Peter Lynch
  264. “Liquidity is only there when you don’t need it.” -Old Proverb
  265. “If you want to be a millionaire, start with a billion dollars and launch a new airline.” – Richard Branson
  266. “Fear incites human action far more urgently than does the impressive weight of historical evidence.” – Jeremy Siegel
  267. “In investing, what is comfortable is rarely profitable.” – Robert Arnott
  268. “Spend each day trying to be a little wiser than you were when you woke up.” – Charlie Munger
  269. “The entrance strategy is actually more important than the exit strategy.” – Edward Lampert
  270. “The rivers don’t drink their own water; Trees don’t eat their own fruits. The sun does not shine for itself, And flowers do not spread their fragrance For themselves. Living for others is a rule of nature” – Pope Francis
  271. “It is impossible to produce superior performance unless you do something different from the majority.” – John Templeton
  272. “An investment in knowledge pays the best interest.” – Benjamin Franklin.
  273. I believe the returns on investment in the poor are just as exciting as successes achieved in the business arena, and they are even more meaningful!” -Bill Gates
  274. “Every portfolio benefits from bonds; they provide a cushion when the stock market hits a rough patch. But avoiding stocks completely could mean your investment won’t grow any faster than the rate of inflation.” – Suze Orman
  275. “The tax on capital gains directly affects investment decisions, the mobility, and flow of risk capital… the ease or difficulty experienced by new ventures in obtaining capital, and thereby the strength and potential for growth in the economy.” – John F. Kennedy
  276. “If all the economists were laid end to end, they’d never reach a conclusion. -George Bernard Shaw
  277. “There are old traders and there are bold traders, but there are very few old, bold traders.”-Ed Seykota
  278. “Let this scenario play out on its own, in its own fashion. As you watch it unfold, you will soon be grateful that you choose the peaceful path. Remember — those who live by the sword, die by the sword.”
  279. “As long as you enjoy investing, you’ll be willing to do the homework and stay in the game.” -Jim Cramer
  280. “I rarely think the market is right. I believe non-dividend stocks aren’t much more than baseball cards. They are worth what you can convince someone to pay for it.” -Mark Cuban
  281. Michael Marcus taught me one other thing that is absolutely critical: You have to be willing to make mistakes regularly; there is nothing wrong with it. Michael taught me about making your best judgment, being wrong, making your next best judgment, being wrong, making your third best judgment, and then doubling your money.” -Bruce Kovner
  282. “The policy of being too cautious is the greatest risk of all.” -Jawaharlal Nehru
  283. “The only true test of whether a stock is “cheap” or “high” is not its current price in relation to some former price, no matter how accustomed we may have become to that former price, but whether the company’s fundamentals are significantly more or less favorable than the current financial-community appraisal of that stock.” -Philip Fisher
  284. “I learned to avoid trying to catch up or double up to recoup losses. I also learned that a certain amount of loss will affect your judgment, so you have to put some time between that loss and the next trade.” -Richard Dennis
  285. “The four most dangerous words in investing are: ‘this time it’s different.” -Sir John Templeton
  286. “Money doesn’t make you happy. I now have $50 million but I was just as happy when I had $48 million.” -Arnold Schwarzenegger

Videos

Please consider viewing these interesting videos: